Cancer Research
Spinal Delivery of Rituximab Tested for Brain and Spine Lymphoma Involvement
MD Anderson's Phase 1/2 trial explored injecting rituximab directly into spinal fluid to target CNS lymphoid malignancies.
Clinical Trial
Jun 16, 2026 0
Results for "Plasma Dilution Therapy" in Cancer
20 articles
Cancer Research
DNA Therapy Slashes Bad Cholesterol by 50% Without Statin Side Effects
A new DNA-based treatment blocks the PCSK9 protein, cutting LDL cholesterol by nearly 50% while avoiding common statin side effects.
Press Release
May 2, 2026 0
Cancer Research
Dual Immunotherapy Achieves 51% Complete Response in Rare Aggressive Lymphoma
Combining CD38 and PD-1 inhibitors produced durable remissions in relapsed NK/T-cell lymphoma, with median response duration exceeding 29 months.
Research Paper
Jun 1, 2026 0
Cancer Research
HaemaLogiX Develops Precision Immunotherapy Targeting Multiple Myeloma Cancer Cells
Australian biotech company creates targeted treatment that attacks malignant plasma cells while sparing healthy ones in multiple myeloma patients.
Press Release
Mar 28, 2026 1
Cancer Research
Talquetamab Shows 60% Response Rate in Japanese Myeloma Patients with No Dose-Limiting Toxicity
Phase 1 data from 15 heavily pretreated Japanese myeloma patients confirms talquetamab's safety and efficacy, matching global trial results.
Research Paper
Jun 15, 2026 0
Cancer Research
Immunotherapy Plus T-DXd Shows Strong Results in HER2-Low Breast Cancer
The BEGONIA trial finds durvalumab combined with trastuzumab deruxtecan achieves 62% response rate in hard-to-treat metastatic breast cancer.
Research Paper
Jun 9, 2026 0
Cancer Research
Modified T Cells Show Promise Against Childhood Blood Cancers in NCI Trial
Researchers modified children's own immune cells to fight B-cell leukemia and lymphoma when standard treatments failed.
Clinical Trial
Mar 28, 2026 0
Cancer Research
CAR T-Cell Therapy Shows Promise Against Relapsed Blood Cancers in Small Trial
Engineered immune cells target CD19+ cancer cells in patients with treatment-resistant lymphoma and leukemia.
Clinical Trial
Mar 28, 2026 1
Cancer Research
Enhanced CAR-T Cell Therapy Shows Promise Against Treatment-Resistant Blood Cancers
Modified immune cells engineered to overcome cancer's defenses completed safety testing in lymphoma patients.
Clinical Trial
Mar 29, 2026 12
Cancer Research
Injecting Immunotherapy Directly Into the Brain Spine Fluid Shows Promise for Deadly Cancer Stage
A phase 1 trial finds intraventricular nivolumab is safe for leptomeningeal metastases, with median survival of 6.6 months.
Research Paper
Jun 5, 2026 0
Cancer Research
Immunotherapy Eliminates Early-Stage Tumors Without Surgery in 82% of Patients
Groundbreaking study shows PD-1 blockade achieves complete tumor elimination in most mismatch repair-deficient cancers, avoiding surgery.
Research Paper
Apr 16, 2026 0
Cancer Research
Morning Immunotherapy Doubles Survival Time in Lung Cancer Trial
A phase 3 trial finds scheduling immunochemotherapy before 3 PM nearly doubles progression-free and overall survival in NSCLC patients.
Research Paper
Jun 1, 2026 0
Cancer Research
Brain Cancer Trial Uses Patient's Own Tumor Cells to Train Immune System
Innovative immunotherapy approach converts patient tumor cells into personalized vaccines to fight aggressive brain cancer.
Clinical Trial
Mar 28, 2026 0
Cancer Research
Pfizer Terminates Phase 1 Trial of Novel Anti-PD-1/IL-15 Fusion Protein in Solid Tumors
Pfizer's first-in-human trial of PF-07209960, a dual-action immunotherapy fusion protein, was terminated after enrolling 37 patients.
Clinical Trial
May 14, 2026 0
Cancer Research
Low-Dose Ipilimumab Plus Pembrolizumab Targets Melanoma Brain Metastases
A completed Phase II trial tests whether combining two checkpoint inhibitors can safely and effectively treat melanoma that has spread to the brain.
Clinical Trial
May 7, 2026 0
Cancer Research
GDF11 Protein Drives Anemia in Blood Cancer by Creating Defective Gene Variants
New research reveals how a specific protein causes anemia in myelodysplastic syndromes and predicts treatment response.
Research Paper
Apr 5, 2026 0
Cancer Research
Dormant Breast Cancer Cells Slashed 80–87% by Repurposed Drugs in Phase 2 Trial
A randomized trial shows hydroxychloroquine and everolimus can dramatically reduce dormant tumor cells in breast cancer survivors, potentially preventing relapse.
Research Paper
May 21, 2026 0
Cancer Research
Triple Immune Checkpoint Blockade Tested in Advanced Solid Tumors
A Phase 1/2 trial explores combining KIR, PD-1, and CTLA-4 inhibitors to unlock stronger anti-tumor immunity.
Clinical Trial
May 20, 2026 0
Cancer Research
Blood Test Reveals Hidden Cancer Resistance in Prostate Cancer Patients
New study shows circulating tumor cells can predict treatment response and reveal drug resistance patterns.
Research Paper
Mar 29, 2026 0
Cancer Research
TROP2 Antibody-Drug Conjugates Target the Hidden Survivors of Lung Cancer Therapy
A new 'induce-target-kill' strategy uses TROP2-directed ADCs to eliminate drug-tolerant persister cells in EGFR-mutant lung cancer.
Research Paper
Jun 19, 2026 0
Page 1 of 2Next